Cell therapy and patient safety
BMS Zola-Cel in Multiple Sclerosis: Patient Death, Early Data and Trial Safety
Understand FDA real-world evidence principles, AI model credibility, digital-twin limitations and the role of oncology trial data quality.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
Bristol Myers Squibb disclosed interim findings from the multiple sclerosis cohorts of Breakfree-2, a Phase 1, single-arm study of investigational CD19-directed CAR-T therapy zolacabtagene autoleucel (zola-cel). Safety was the primary endpoint. The analysis included 66 participants with highly active relapsing or progressive MS despite prior treatment.
After the data cutoff, a participant with highly active relapsing MS died of septic pneumonia, 44 days after infusion. BMS described late-onset motor symptoms classified as non-ICANS that did not resolve with intermittent corticosteroids and intravenous immunoglobulin. High-dose cyclophosphamide was subsequently administered; the patient developed septic pneumonia and died the following day. The sequence alone does not establish the causal contribution of zola-cel, subsequent interventions or other factors.
BMS told Fierce Biotech that the death was separate from the inflammatory events that prompted its earlier enrollment pause. That statement should not be interpreted as establishing that the death was unrelated to treatment. In the October 26 report, the company said it was working with health authorities toward restarting trials; this was not confirmation of restart authorization.
The efficacy observations are preliminary. All 60 participants at dose level 2 remained off disease-modifying therapies at last follow-up, but only nine had more than 12 months of follow-up. Among 24 evaluable participants with progressive MS and at least 26 weeks of follow-up, 22 (92%) showed stable or improved disability. This percentage does not describe the full study population.
Cytokine release syndrome occurred in 28 of 66 participants (42.4%), with Grade 1 or 2 events that resolved. ICANS occurred in five participants, including one Grade 4 event that resolved with treatment. The uncontrolled study cannot establish comparative safety, durable remission or a cure.
What this means for trial teams
Lampgen’s interpretation is that the potential to reduce reliance on chronic therapy warrants rigorous investigation, alongside a clear account of serious harms. The clinical significance of these findings will depend on longer follow-up, controlled evidence and an acceptable benefit–risk profile for defined patient populations.
For trial teams, priorities include reliable capture of delayed neurological changes, clear investigator and medical-monitor escalation pathways, infection surveillance and complete timelines linking symptoms, rescue interventions and outcomes. CRAs support documentation, protocol compliance and escalation; medical assessment and treatment decisions remain with qualified investigators and medical teams.
Consent discussions should evolve as the evidence changes. Participants need understandable information about known risks, unresolved questions and available alternatives. A treatment-free interval should not be presented as proof of cure or lifelong remission.
Oncology CAR-T experience offers useful operational lessons, but autoimmune development requires disease-specific judgments about treatment alternatives, disability and patient expectations. Lampgen specializes in oncology CRA staffing and clinical-operations support. Our perspective is that relevant experience, prepared sites and timely escalation help teams generate evidence that patients and regulators can evaluate.
This analysis reflects the October 23 and October 26, 2026 disclosures. It does not establish a subsequent regulatory decision or trial restart.